|
1
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adams S, Loi S, Toppmeyer D, Cescon DW, De
Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, et
al: Pembrolizumab monotherapy for previously untreated,
PD-L1-positive, metastatic triple-negative breast cancer: Cohort B
of the phase II KEYNOTE-086 study. Ann Oncol. 30:405–411. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Emens LA, Cruz C, Eder JP, Braiteh F,
Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, et
al: Long-term clinical outcomes and biomarker analyses of
atezolizumab therapy for patients with metastatic triple-negative
breast cancer: A phase 1 study. JAMA Oncol. 5:74–82. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell Infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Emens LA, Loi S, Rugo HS, Schneeweiss A,
Diéras V, Iwata H, Barrios CH, Nechaeva M, Molinero L, Duc AN, et
al: Abstract GS1-04: IMpassion130: Efficacy in immune biomarker
subgroups from the global, randomized, double-blind,
placebo-controlled, phase III study of atezolizumab +
nab-paclitaxel in patients with treatment-naïve, locally advanced
or metastatic triple-negative breast cancer. Cancer Res. 79 (4
Suppl):GS1–04. 2019.
|
|
13
|
Noy R and Pollard JW: Tumor-associated
macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DeNardo DG and Ruffell B: Macrophages as
regulators of tumour immunity and immunotherapy. Nat Rev Immunol.
19:369–382. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM,
West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC and
DeNardo DG: CSF1/CSF1R blockade reprograms tumor-infiltrating
macrophages and improves response to T-cell checkpoint
immunotherapy in pancreatic cancer models. Cancer Res.
74:5057–5069. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arlauckas SP, Garris CS, Kohler RH,
Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman
GJ, Anthony RM, et al: In vivo imaging reveals a tumor-associated
macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci
Transl Med. 9:eaal36042017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lo Russo G, Moro M, Sommariva M, Cancila
V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber
V, et al: Antibody-Fc/FcR interaction on macrophages as a mechanism
for hyperprogressive disease in non-small cell lung cancer
subsequent to PD-1/PD-L1 blockade. Clin Cancer Res. 25:989–999.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Medrek C, Pontén F, Jirström K and
Leandersson K: The presence of tumor associated macrophages in
tumor stroma as a prognostic marker for breast cancer patients. BMC
Cancer. 12:3062012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miyasato Y, Shiota T, Ohnishi K, Pan C,
Yano H, Horlad H, Yamamoto Y, Yamamoto-Ibusuki M, Iwase H, Takeya M
and Komohara Y: High density of CD204-positive macrophages predicts
worse clinical prognosis in patients with breast cancer. Cancer
Sci. 108:1693–1700. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimada H, Hasebe T, Sugiyama M, Shibasaki
S, Sugitani I, Ueda S, Gotoh Y, Yasuda M, Arai E, Osaki A and Saeki
T: Fibrotic focus: An important parameter for accurate prediction
of a high level of tumor-associated macrophage infiltration in
invasive ductal carcinoma of the breast. Pathol Int. 67:331–341.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hatogai K, Kitano S, Fujii S, Kojima T,
Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T and
Ochiai A: Comprehensive immunohistochemical analysis of tumor
microenvironment immune status in esophageal squamous cell
carcinoma. Oncotarget. 7:47252–47264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs working group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mohammed ZM, Going JJ, Edwards J,
Elsberger B, Doughty JC and McMillan DC: The relationship between
components of tumour inflammatory cell infiltrate and
clinicopathological factors and survival in patients with primary
operable invasive ductal breast cancer. Br J Cancer. 107:864–873.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miglietta F, Griguolo G, Guarneri V and
Dieci MV: Programmed cell death ligand 1 in breast cancer:
Technical aspects, prognostic implications, and predictive value.
Oncologist. 24:e1055–e1069. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lehmann BD, Jovanović B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of triple-negative breast cancer molecular subtypes:
Implications for neoadjuvant chemotherapy selection. PLoS One.
11:e01573682016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harano K, Wang Y, Lim B, Seitz RS, Morris
SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, et al: Rates
of immune cell infiltration in patients with triple-negative breast
cancer by molecular subtype. PLoS One. 13:e02045132018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kroemer G, Galluzzi L, Kepp O and Zitvogel
L: Immunogenic cell death in cancer therapy. Annu Rev Immunol.
31:51–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mahmoud SM, Lee AH, Paish EC, Macmillan
RD, Ellis IO and Green AR: Tumour-infiltrating macrophages and
clinical outcome in breast cancer. J Clin Pathol. 65:159–163. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tiainen S, Tumelius R, Rilla K, Hämäläinen
K, Tammi M, Tammi R, Kosma VM, Oikari S and Auvinen P: High numbers
of macrophages, especially M2-like (CD163-positive), correlate with
hyaluronan accumulation and poor outcome in breast cancer.
Histopathology. 66:873–883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Z, Maeda D, Yoshida M, Umakoshi M,
Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, et al:
The intratumoral distribution influences the prognostic impact of
CD68- and CD204-positive macrophages in non-small cell lung cancer.
Lung Cancer. 123:127–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ichimura T, Abe H, Morikawa T, Yamashita
H, Ishikawa S, Ushiku T, Seto Y and Fukayama M: Low density of
CD204-positive M2-type tumor-associated macrophages in Epstein-Barr
virus-associated gastric cancer: A clinicopathologic study with
digital image analysis. Hum Pathol. 56:74–80. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yagi T, Baba Y, Okadome K, Kiyozumi Y,
Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe
M, et al: Tumour-associated macrophages are associated with poor
prognosis and programmed death ligand 1 expression in oesophageal
cancer. Eur J Cancer. 111:38–49. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Adams S, Schmid P, Rugo HS, Winer EP,
Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, et al:
Pembrolizumab monotherapy for previously treated metastatic
triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086
study. Ann Oncol. 30:397–404. 2019. View Article : Google Scholar : PubMed/NCBI
|
